cooperative-group

The AGO Study Group is the German gynaecological oncology trials group, founded in 1993 as AGO-OVAR to improve ovarian cancer treatment; it sponsors DESKTOP III and four other ovarian and vulvar cancer trials in OnCo.

The AIDS Malignancy Consortium is the US National Cancer Institute-supported trials group for cancers in people with HIV, founded in 1995 with 38 sites worldwide; in OnCo it leads ANCHOR, the trial showing that treating anal precancer prevents anal cancer.

Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups.

AIO is the medical oncology working group of the German Cancer Society, founded in 1976 with about 1,500 members; its trials company AIO-Studien-gGmbH sponsors the NALIRICC, NIFE and FLOT4 trials in OnCo and co-ran FIRE-3 and SSG XVIII.

ALFA is the French adult acute myeloid leukaemia cooperative group, an association founded in 1998 of clinicians, biologists and research assistants across 33 centres; in OnCo it leads ALFA-0701, the trial that brought gemtuzumab ozogamicin back.

US cooperative group formed from CALGB, ACOSOG, and NCCTG; running OptimICE-pCR, which asks whether TNBC patients with a complete response still need a year of immunotherapy.

Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer.

The Australian genitourinary trials group behind TheraP and proPSMA, the trials that put PSMA imaging and lutetium-PSMA therapy on the map.

The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.

Australia and New Zealand's gastrointestinal cancer trials group, running practice-informing trials in gastric, oesophageal, colorectal and pancreatic cancer, including ctDNA-guided adjuvant studies.

Austria's academic breast and colorectal trials group, whose bone-targeted and extended endocrine therapy trials changed breast cancer practice.

Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.

The Australian and New Zealand breast cancer trials group, a Breast International Group partner in SOFT/TEXT, APHINITY, OlympiA and POSITIVE.

The Breast International Group is the umbrella for 50+ academic breast cancer groups worldwide and co-sponsor of OlympiA, APHINITY, and HERA.

Canada's national academic trials group, which ran the CHALLENGE exercise trial and co-led the SABR-COMET oligometastasis trial.

The UK and Ireland's professional body and trials network for children's cancer; nearly every child treated for cancer in the UK is cared for by a CCLG centre.

The Children's Oncology Group is the world's largest paediatric cancer trials organisation; most children with cancer in North America are treated on or according to a COG protocol.

CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.

Kiel professor of medicine who serves as President of the German Lymphoma Alliance, the umbrella body for German lymphoma study groups, alongside co-president Georg Lenz.

DAHANCA, the Danish Head and Neck Cancer Group established in September 1976, writes Denmark's head and neck cancer guidelines and ran the numbered DAHANCA radiotherapy trials, including DAHANCA 5 on the radiosensitiser nimorazole in OnCo.

The Danish Breast Cancer Group, established by the Danish Surgical Society in 1976, writes Denmark's national breast cancer guidelines, keeps the national database and ran the DBCG 82b and 82c postmastectomy radiotherapy trials in OnCo.

The Dutch Pancreatic Cancer Group is the national Dutch collaboration of pancreatic cancer surgeons, oncologists and researchers that ran PREOPANC, the trial that established neoadjuvant chemoradiotherapy for resectable pancreatic cancer.

US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.

EORTC is Europe's academic cancer trials organisation and has run practice-changing trials since 1962.

The Bern-based foundation that unites the International Breast Cancer Study Group (SOFT, TEXT, POSITIVE) and the European Thoracic Oncology Platform.

The European Myeloma Network is the non-profit network of European myeloma haematologists created from 2005 to run shared research and trials; its Dutch foundation is the registry sponsor of CARTITUDE-6 in OnCo.

FILO is the French cooperative group for leukaemia trials, with its registered office in the haematology department of the Tours university hospital; in OnCo it leads a phase 2 trial of eltrombopag in older patients with acute myeloid leukaemia.

The Fondazione Italiana Linfomi is Italy's non-profit lymphoma trials foundation, constituted in 2010 out of the Intergruppo Italiano Linfomi of 1994 and working with more than 150 Italian centres; in OnCo it leads two lymphoma trials.

The French Sarcoma Group is the national cooperative group for soft tissue and bone sarcoma trials in France; in OnCo it is the sponsor of ANGIOTAX and the group behind LMS-04 and CABONE.

Spain's national breast cancer research group, running adjuvant chemotherapy, endocrine and CDK4/6 inhibitor trials across more than 200 hospitals.

GERCOR is a French non-profit cooperative group created in 1997 that sponsors its own phase 2 and 3 solid tumour trials through a network of about 300 investigators; in OnCo it leads LAP07 in locally advanced pancreatic cancer.

The German academic group whose GeparX trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer.

The German CLL Study Group, founded in 1996 at the University of Cologne, runs the numbered CLL trials that set first-line treatment of chronic lymphocytic leukaemia, including CLL12, CLL13 (GAIA) and CLL14 in OnCo.

The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.

Germany's aggressive lymphoma trials group, formerly DSHNHL, whose MInT, RICOVER-60 and FLYER trials set how many cycles of R-CHOP patients need.

Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.

The US gynaecologic oncology trials organisation whose GOG-3000-series trials with industry brought immunotherapy into endometrial and cervical cancer.

GORTEC is the French head and neck radiotherapy and oncology group, an association founded in 1999 that runs the academic trials behind much of the standard of care in head and neck cancer, including TPExtreme and NIVOPOSTOP in OnCo.

The Hellenic Oncology Research Group is a Greek non-profit of oncologists and scientists that runs its own cancer trials; in OnCo it leads three phase 3 adjuvant breast cancer trials.

The Dutch-Belgian adult haematology trials group, one of Europe's largest engines of leukaemia, myeloma and lymphoma phase 3 trials.

Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.

Europe's network of children's hospitals that run the first trials of new cancer drugs in children, so that European children can access experimental medicines close to home.

The French thoracic oncology intergroup, which ran the national Biomarkers France programme showing that routine molecular testing of lung cancer improves survival.

The IFM is the French-speaking myeloma cooperative group created in 1994, with 140 French and 33 Belgian centres, whose trials set melphalan-autograft intensification, bortezomib induction and lenalidomide maintenance; in OnCo it leads CASSIOPEIA and IFM 2009.

A Swiss-based international group that runs the trials defining treatment of rare extranodal lymphomas, including primary CNS lymphoma and gastric MALT lymphoma.

The Italian Sarcoma Group is the Italian non-profit collaborative group for soft tissue, GIST and bone sarcoma research, constituted in June 1997; in OnCo it leads ISG-STS 1001, the histology-tailored neoadjuvant chemotherapy trial.

JCOG is Japan's national cooperative group and defines surgical and perioperative standards in gastric and oesophageal cancer.

Led the COG renal tumour committee that used biology to tailor Wilms tumour treatment.

Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.

South Korea's multicentre cooperative trials group, linking the Seoul mega-hospitals and regional centres in investigator-initiated trials in gastric, lung, liver and breast cancer.

The Korean Gynecologic Oncology Group is the Korean incorporated association that runs gynaecological cancer trials; in OnCo it leads a phase 2 study of progestin with a levonorgestrel intrauterine system for fertility-sparing treatment of early endometrial cancer.

Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result.

The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.

Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.

The MRC Clinical Trials Unit at UCL is the UK public trials unit that designed and ran STAMPEDE, FOCUS4, ICON7 and UKCTOCS; it marked 25 years in 2024 and became the UCL Innovative Clinical Trials Unit in April 2026.

Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.

The Danish, Finnish, Norwegian, Swedish and Icelandic lymphoma trials network, best known for the Nordic mantle cell lymphoma regimen.

The US cooperative group formed from the radiation, gynaecologic, and breast trial groups; it co-led OlympiA, the trial that put a PARP inhibitor after surgery for BRCA carriers.

The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.

The Ontario Clinical Oncology Group is a Canadian academic trials group based at the Juravinski Hospital in Hamilton that designs and runs investigator-led cancer trials; in OnCo it leads LUMINA, the radiotherapy-omission study in low-risk luminal A breast cancer.